Literature DB >> 25557626

Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.

Grzegorz Garbacz1, Gerd-Martin Rappen, Mirko Koziolek, Werner Weitschies.   

Abstract

OBJECTIVES: For the treatment of inflammatory bowel disease, the development of pH responsive modified release dosage forms is one of the most common approaches to achieve targeted drug delivery. In this study, the dissolution behaviour of eight different modified release (MR) products containing 800 mg mesalazine was investigated.
METHODS: The performance of the products was compared under simulated fasted state conditions using the paddle apparatus as well as the dissolution stress test device mimicking mechanical stress events of bio-relevant intensity. KEY
FINDINGS: The dissolution behaviour of the eight tested different pH-responsive MR tablets containing 800 mg mesalazine was dependent on the test conditions. Phases of mechanical stress with physiological intensity influenced the dissolution characteristics and caused in some cases accelerated drug release indicating possible dose dumping.
CONCLUSION: The study demonstrates that besides the investigation of the pH dependency of drug release, the characterisation of the mechanical robustness of the dosage forms is an essential factor determining the dissolution characteristics of such pH-dependent targeted modified release tablets. The susceptibility of 800 mg mesalazine MR tablets towards mechanical stress may be one reason for undesired drug delivery in vivo.
© 2014 Royal Pharmaceutical Society.

Entities:  

Keywords:  bio-relevant dissolution testing; burst release mesalazine; carbonate buffer; dissolution stress test; dose dumping

Mesh:

Substances:

Year:  2014        PMID: 25557626     DOI: 10.1111/jphp.12332

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

Review 1.  In Vitro Methodologies for Evaluating Colon-Targeted Pharmaceutical Products and Industry Perspectives for Their Applications.

Authors:  Mauricio A García; Felipe Varum; Jozef Al-Gousous; Michael Hofmann; Susanne Page; Peter Langguth
Journal:  Pharmaceutics       Date:  2022-01-26       Impact factor: 6.321

2.  Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial.

Authors:  Ewelina Juszczyk; Kamil Kisło; Paweł Żero; Ewa Tratkiewicz; Maciej Wieczorek; Jadwiga Paszkowska; Grzegorz Banach; Marcela Wiater; Dagmara Hoc; Grzegorz Garbacz; Jaroslaw Sczodrok; Dorota Danielak
Journal:  Pharmaceutics       Date:  2021-05-28       Impact factor: 6.321

3.  IVIVC for Extended Release Hydrophilic Matrix Tablets in Consideration of Biorelevant Mechanical Stress.

Authors:  Valentyn Mohylyuk; Seyedreza Goldoozian; Gavin P Andrews; Andriy Dashevskiy
Journal:  Pharm Res       Date:  2020-10-22       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.